Artrya Ltd (ASX: AYA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Artrya Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$43.91 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
92.42 million
Earnings per share
-0.178
Dividend per share
N/A
Year To Date Return
100.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Artrya Ltd (ASX: AYA)
Latest News
IPOs
New artificial intelligence ASX share rockets 13% on debut
Technology Shares
Move over Appen: A new artificial intelligence stock to list on the ASX
Frequently Asked Questions
-
No, Artrya has not yet paid dividends to shareholders.
-
The company, founded in 2019 in Perth, listed on the ASX on 26 November 2021.
AYA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Artrya Ltd
Artrya Ltd (ASX: AYA) is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease. Artrya’s Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.
The Perth-based company says the technology will revolutionise the speed and accuracy of coronary artery disease diagnosis.
AYA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.48 | $0.01 | 2.13% | 40,216 | $0.48 | $0.50 | $0.48 |
| 19 Dec 2024 | $0.47 | $0.01 | 2.17% | 116,033 | $0.45 | $0.48 | $0.45 |
| 18 Dec 2024 | $0.46 | $-0.02 | -4.21% | 20,112 | $0.48 | $0.48 | $0.46 |
| 17 Dec 2024 | $0.48 | $0.00 | 0.00% | 604,494 | $0.48 | $0.48 | $0.48 |
| 16 Dec 2024 | $0.48 | $0.03 | 6.67% | 121,372 | $0.46 | $0.48 | $0.45 |
| 13 Dec 2024 | $0.45 | $-0.01 | -2.17% | 117,256 | $0.45 | $0.46 | $0.43 |
| 12 Dec 2024 | $0.46 | $0.01 | 2.20% | 10,730 | $0.46 | $0.46 | $0.45 |
| 11 Dec 2024 | $0.46 | $-0.02 | -4.21% | 12,262 | $0.48 | $0.48 | $0.44 |
| 10 Dec 2024 | $0.48 | $0.02 | 4.35% | 44,311 | $0.48 | $0.48 | $0.45 |
| 09 Dec 2024 | $0.46 | $-0.09 | -16.51% | 137,701 | $0.53 | $0.53 | $0.46 |
| 06 Dec 2024 | $0.55 | $0.03 | 5.83% | 12,941 | $0.52 | $0.55 | $0.52 |
| 05 Dec 2024 | $0.52 | $-0.01 | -1.90% | 57,802 | $0.54 | $0.54 | $0.51 |
| 04 Dec 2024 | $0.53 | $0.01 | 1.92% | 20,968 | $0.53 | $0.54 | $0.52 |
| 03 Dec 2024 | $0.52 | $0.02 | 4.00% | 381,626 | $0.50 | $0.56 | $0.50 |
| 02 Dec 2024 | $0.50 | $0.06 | 13.64% | 243,834 | $0.44 | $0.50 | $0.43 |
| 29 Nov 2024 | $0.44 | $0.00 | 0.00% | 1,517 | $0.44 | $0.44 | $0.44 |
| 28 Nov 2024 | $0.44 | $0.01 | 2.33% | 15,495 | $0.42 | $0.44 | $0.42 |
| 27 Nov 2024 | $0.43 | $0.02 | 4.88% | 17,283 | $0.42 | $0.44 | $0.42 |
| 26 Nov 2024 | $0.41 | $-0.01 | -2.38% | 34,603 | $0.42 | $0.42 | $0.41 |
| 25 Nov 2024 | $0.42 | $-0.02 | -4.60% | 68,459 | $0.44 | $0.45 | $0.42 |
| 22 Nov 2024 | $0.44 | $-0.02 | -4.44% | 9,083 | $0.44 | $0.44 | $0.44 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Bernard (Bernie) William Ridgeway | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
Mr Ridgeway brings corporate experience to Artrya, including 38 years in private and ASX-listed companies, spending most of that time in the role of Managing Director. His vision is for Artrya to become the global standard in non-invasive AI and machine learning to diagnose and treat coronary artery disease.
|
| Dr Jacque Sokolov | Non-Executive Director | Aug 2022 |
Dr Sokolov has experience across all aspects of the US healthcare industry, in healthcare delivery, biotechnology, and regulatory clearance. Dr. Sokolov is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US healthcare management, development, and financial services company. His company has worked with more than 100 healthcare organisations across US healthcare sectors to develop physician-driven, value-focused solutions in evolving markets. He currently serves on public, private and not-for-profit healthcare boards. He is focused on leading technology involving advanced digital health and next generation genetic-based companies. Over the past 3 years, board appointments in the US listed companies: Lucid Diagnostics, Inc. (NASDAQ: LUCD) 2021-Present, Chairman of Compliance & Quality Committee and Member of Audit & Compensation Committees; MedCath Corporation (NASDAQ: MDTH) 2004-2021, Chairman of Compliance/Quality Committee.
|
| Ms Catherine (Kate) Hill | Non-Executive Director | Feb 2023 |
Ms Hill is an experienced non-executive director of ASX listed companies and has expertise at board level in technology companies and also the biotech and medical devices sectors. In addition, she has experience of other listing exchanges including Nasdaq (US) and AIM (UK). Kate previously spent over 20 years as an audit partner at Deloitte, serving both ASX-listed and privately owned clients. She has worked in regulated environments, including assisting with Initial Public Offerings, capital raising, and general compliance, as well as operating in an audit environment.
|
| Mr Kevin R Hart | Company Secretary | Oct 2022 |
-
|
| Mathew Regan | Chief Executive Officer |
-
|
|
| Kevin R Hart | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr John Barrington <Bht Family A/C> | 7,117,945 | 9.04% |
| Ms Erika Henriette Konstantopoulos <Iemk Family A/C> | 7,000,000 | 8.89% |
| Richcab Pty Ltd <Dale Mckenzie Super Fund A/C> | 4,128,115 | 5.25% |
| Mutual Trust Pty Ltd | 3,992,459 | 5.07% |
| Rubino Group Pty Ltd <Rubino Group A/C> | 2,423,485 | 3.08% |
| Mr Paul Ernest Neilsen & Mrs Julie Louise Neilsen | 1,856,818 | 2.36% |
| Gaziton Pty Ltd <The Miller Super Fund A/C> | 1,500,000 | 1.91% |
| Ian Sandover & Associates Pty Ltd <Sandover Super A/C> | 1,200,000 | 1.52% |
| Keeble Nominees Pty Ltd <Ridgeway Self Managed Super Fund A/C> | 1,113,637 | 1.42% |
| Stanley Roger Pty Ltd | 1,074,074 | 1.36% |
| Ms Paula Maria Rogers | 1,034,226 | 1.31% |
| Mr Benjamin Richard Lisle & Ms Gina Sarasa Lisle <Ben Lisle Super Fund A/C> | 931,819 | 1.18% |
| Korel Corp Pty Ltd <The Honeypot Super Fund A/C> | 909,092 | 1.16% |
| Montrose Investments (Wa) Pty Ltd <Fraunschiel Family A/C> | 750,000 | 0.95% |
| Mr Adam James Ridgeway | 750,000 | 0.95% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 743,210 | 0.94% |
| UBS Nominees Pty Ltd | 716,181 | 0.91% |
| Sarion Pty Ltd <Fielding Super Fund A/C> | 708,819 | 0.90% |
| Temorex Pty Ltd <Nitram Family A/C> | 704,091 | 0.89% |
| Wear Services Pty Ltd <The Pegasus A/C> | 671,361 | 0.85% |
| Mcalinden Superannuation Pty Ltd <Mcalinden Super Fund A/C> | 600,000 | 0.76% |
